Diversicare Healthcare Services (DVCR) 10-Q 7 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 04, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	Diversicare Healthcare Services, Inc.
Entity Central Index Key	0000919956
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding		6,865,689

INTERIM CONSOLIDATED BALANCE SH

INTERIM CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash	$ 4,163	$ 2,710
Receivables	59,455	60,521
Self-insurance receivables, current portion	1,831	1,011
Other receivables	2,409	2,534
Prepaid expenses and other current assets	3,894	5,056
Income tax refundable	664	484
Total current assets	72,416	72,316
PROPERTY AND EQUIPMENT, at cost	133,701	132,775
Less accumulated depreciation and amortization	(87,174)	(85,020)
Property and equipment, net	46,527	47,755
OTHER ASSETS:
Operating lease right-of-use assets	303,754	310,238
Acquired leasehold interest, net	5,603	5,736
Other noncurrent assets	2,896	4,323
Total other assets	312,253	320,297
Total assets	431,196	440,368
CURRENT LIABILITIES:
Current portion of long-term debt and finance lease obligations	3,467	3,498
Current portion of operating lease liabilities	24,529	23,736
Trade accounts payable	13,651	14,641
Accrued expenses:
Payroll and employee benefits	17,111	16,780
Self-insurance reserves, current portion	14,254	13,829
Other current liabilities	11,158	11,545
Total current liabilities	84,170	84,029
NONCURRENT LIABILITIES:
Long-term debt and finance lease obligations, less current portion and deferred financing costs, net	70,944	70,637
Operating lease liabilities, less current portion	289,187	295,636
Self-insurance reserves, noncurrent portion	14,722	16,291
Litigation contingency, less current portion	8,000	9,000
Other noncurrent liabilities	1,779	1,691
Total noncurrent liabilities	384,632	393,255
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ DEFICIT:
Common stock, authorized 20,000 shares, $.01 par value, 7,098 and 6,908 shares issued, and 6,866 and 6,676 shares outstanding, respectively	70	69
Treasury stock at cost, 232 shares of common stock	(2,500)	(2,500)
Paid-in capital	24,367	24,026
Accumulated deficit	(59,832)	(59,079)
Accumulated other comprehensive income	289	568
Total shareholders’ deficit	(37,606)	(36,916)
Total liabilities and shareholder's equity	$ 431,196	$ 440,368

INTERIM CONSOLIDATED BALANCE _2

INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value (dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (shares)	20,000,000	20,000,000
Common stock, shares issued (shares)	7,098,000	6,908,000
Common stock, shares outstanding (shares)	6,866,000	6,676,000
Treasury stock, shares (shares)	232,000	232,000

INTERIM CONSOLIDATED STATEMENTS

INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
PATIENT REVENUES, net	$ 119,987	$ 117,550
EXPENSES:
Operating	94,859	94,422
Lease and rent expense	13,512	13,115
Professional liability	1,839	1,851
General and administrative	6,758	7,213
Depreciation and amortization	2,288	2,317
Total expenses	119,256	118,918
OPERATING INCOME (LOSS)	731	(1,368)
OTHER INCOME (EXPENSE):
Other income	115	160
Interest expense, net	(1,460)	(1,394)
Total other expense	(1,345)	(1,234)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	(614)	(2,602)
BENEFIT FOR INCOME TAXES	104	1,028
LOSS FROM CONTINUING OPERATIONS	(510)	(1,574)
LOSS FROM DISCONTINUED OPERATIONS:
Operating loss, net of tax benefit of $65 and $73, respectively	(243)	(1,772)
NET LOSS	$ (753)	$ (3,346)
Per common share – basic
Continuing operations (in dollars per share)	$ (0.08)	$ (0.24)
Discontinued operations (in dollars per share)	(0.04)	(0.28)
Net loss per common share – basic (dollars per share)	(0.12)	(0.52)
Per common share – diluted
Continuing operations (in dollars per share)	(0.08)	(0.24)
Discontinued operations (in dollars per share)	(0.04)	(0.28)
Net income (loss) per common share – diluted (dollars per share)	$ (0.12)	$ (0.52)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic (shares)	6,506	6,424
Diluted (shares)	6,506	6,424

INTERIM CONSOLIDATED STATEMEN_2

INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Tax benefit, effect on operating loss	$ 65	$ 73

INTERIM CONSOLIDATED STATEMEN_3

INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
NET LOSS	$ (753)	$ (3,346)
OTHER COMPREHENSIVE INCOME:
Change in fair value of cash flow hedge, net of tax	(279)	(63)
Total other comprehensive loss	(279)	(63)
COMPREHENSIVE LOSS	$ (1,032)	$ (3,409)

INTERIM CONSOLIDATED STATEMEN_4

INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIT - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Treasury Stock	Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Balance (in shares) at Dec. 31, 2018		6,751	232
Balance at Dec. 31, 2018	$ (1,198)	$ 68	$ (2,500)	$ 23,413	$ (23,016)	$ 837
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(3,346)				(3,346)
Issuance/redemption of equity grants, net (in shares)		163
Issuance/redemption of equity grants, net	42	$ 1		41
Interest rate cash flow hedge	(63)					(63)
Stock-based compensation	140			140
Balance (in shares) at Mar. 31, 2019		6,914	232
Balance at Mar. 31, 2019	(4,425)	$ 69	$ (2,500)	23,594	(26,362)	774
Balance (in shares) at Dec. 31, 2019		6,908	232
Balance at Dec. 31, 2019	(36,916)	$ 69	$ (2,500)	24,026	(59,079)	568
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(753)				(753)
Issuance/redemption of equity grants, net (in shares)		190
Issuance/redemption of equity grants, net	4	$ 1		3
Interest rate cash flow hedge	(279)					(279)
Stock-based compensation	338			338
Balance (in shares) at Mar. 31, 2020		7,098	232
Balance at Mar. 31, 2020	$ (37,606)	$ 70	$ (2,500)	$ 24,367	$ (59,832)	$ 289

INTERIM CONSOLIDATED STATEMEN_5

INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
NET LOSS	$ (753)	$ (3,346)
Loss from discontinued operations	(243)	(1,772)
Loss from continuing operations	(510)	(1,574)
Adjustments to reconcile loss from continuing operations to net cash provided by operating activities:
Depreciation and amortization	2,288	2,317
Deferred income tax benefit	0	(1,090)
Provision for self-insured professional liability, net of cash payments	173	1,444
Amortization of right-of-use assets	5,663	5,125
Stock-based and deferred compensation	338	156
Provision for leases in excess of cash payments	821	1,280
Other	517	335
Changes in assets and liabilities affecting operating activities:
Receivables	246	5,315
Prepaid expenses and other assets	792	(2,966)
Trade accounts payable and accrued expenses	(2,021)	(3,293)
Operating lease liabilities	(5,656)	(5,101)
Net cash provided by continuing operations	2,651	1,948
Discontinued operations	(243)	(1,609)
Net cash provided by operating activities	2,408	339
NET CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(927)	(1,186)
Net cash used in continuing operations	(927)	(1,186)
Discontinued operations	0	(312)
Net cash used in investing activities	(927)	(1,498)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt and finance lease obligations	(2,113)	(1,112)
Proceeds from issuance of debt	2,500	2,049
Financing costs	(419)	(40)
Issuance and redemption of employee equity awards, net	4	42
Net cash provided by (used in) continuing operations	(28)	939
Discontinued operations	0	0
Net cash provided by (used in) financing activities	(28)	939
NET INCREASE (DECREASE) IN CASH	1,453	(220)
CASH, beginning of period	2,710	2,685
CASH, end of period	4,163	2,465
SUPPLEMENTAL INFORMATION:
Cash payments of interest	1,599	1,829
Cash payments of income taxes	10	426
SUPPLEMENTAL INFORMATION ON NON-CASH INVESTING AND FINANCING TRANSACTIONS:
Acquisition of equipment through finance leases	0	49
Acquisition of operating leases though adoption of ASC 842	$ 0	$ 389,403

BUSINESS

BUSINESS	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS	BUSINESS Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in nine states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Mississippi, Missouri, Ohio, Tennessee, and Texas. As of March 31, 2020 , the Company’s continuing operations consist of 62 nursing centers with 7,329 licensed nursing beds. The Company owns 15 and leases 47 of its nursing centers. Our nursing centers range in size from 50 to 320 licensed nursing beds. The licensed nursing bed count does not include 397 licensed assisted and residential living beds. Recent Developments In March 2020, the World Health Organization categorized the disease known as COVID-19 that is caused by a novel coronavirus (“COVID-19”), as a pandemic. The President of the United States declared the COVID-19 outbreak a national emergency. The Centers for Medicare & Medicaid Services (“CMS”) and the Centers for Disease Control and Prevention (“CDC”) have issued guidance to state and local governments and long-term care facilities to help mitigate the spread of COVID-19. On March 13, 2020, CMS and CDC issued a prohibition of visitors to long-term care facilities as a precaution to keep residents and patients safe. Additionally, on March 23, 2020, CMS announced new, focused infection control surveys intended to assess long-term care facility compliance with infection control requirements in connection with the COVID-19 pandemic. On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) which includes, among other things, modifications to the limitation on business interest expense and net operating loss provisions, allows an optional payment deferral of employer payroll taxes during 2020 after the date of enactment and the appropriation of stimulus funds to Medicare and Medicaid providers. On April 24, 2020, the Paycheck Protection Program and Health Care Enhancement Act ("PPPHCE Act") was enacted, which provides for additional emergency appropriations for COVID-19 response. We continue to examine the impact that the CARES Act may have on our business. Currently, we are unable to determine the full impact that the CARES Act will have on our financial condition, results of operations, or liquidity. The Company is closely monitoring and evaluating the impact of the COVID-19 pandemic on all aspects of its business. We have identified team members and patients who have tested positive for COVID-19 at a select number of our centers, and we have incurred an increase in the costs of caring for the patients and residents in those centers. The Company has also experienced reduced occupancy at its centers and has incurred additional expenditures preparing our centers for potential outbreaks. The Company has an interdisciplinary team monitoring and staying up to date on the latest information about the virus and its prevalence. The Company has implemented precautionary measures and response protocols to minimize the spread of the virus, following guidance from the CDC, but the Company nevertheless expects additional cases of the virus will occur at these and other facilities. The Company is continuing to evaluate and consider the potential impact that the virus may have on its liquidity, financial condition and results of operations due to numerous uncertainties. However, given the uncertainty as to the duration of the COVID-19 pandemic, it could have a material adverse effect on the Company's future results of operations, financial condition and liquidity. Refer to Notes 9, “Income Taxes,” and 13, “Subsequent Events” for more information.

CONSOLIDATION AND BASIS OF PRES

CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS	CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS The interim consolidated financial statements for the three month periods ended March 31, 2020 and 2019 , included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at March 31, 2020 , and the results of operations, and changes in shareholders' deficit and cash flows for the three month periods ended March 31, 2020 and 2019 . The Company’s balance sheet information at December 31, 2019 , was derived from its audited consolidated financial statements as of December 31, 2019 . Effective January 1, 2019, we adopted the requirements of Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842), as discussed in Notes 3 and 6 to the interim consolidated financial statements. All amounts and disclosures set forth in these financial statements comply with the new standard. The results of operations for the periods ended March 31, 2020 and 2019 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 . Discontinued Operations On December 1, 2018, the Company sold three Kentucky properties for a purchase price of $18.7 million , which are collectively referred to as the "Kentucky Properties." On August 30, 2019, the Company terminated operations of ten centers in Kentucky and concurrently transferred operations to a new operator. These ten centers are collectively referred to as the "Kentucky Centers." The sale of the Kentucky Properties and the termination of operations at the Kentucky Centers are referred to collectively as the "Kentucky Exit." As a result of the Kentucky Exit, the Company no longer operates any skilled nursing centers in the State of Kentucky. The Company's exit from the state represents a strategic shift that has (or will have) a major effect on the Company's financial position, results of operations and cash flows. In accordance with ASC 205, the Company's discontinued operating results have been reclassified on the face of the financial statements and footnotes for all periods presented to reflect the discontinued status of these operations. Refer to Note 12, "Discontinued Operations" for more information.

RECENT ACCOUNTING GUIDANCE

RECENT ACCOUNTING GUIDANCE	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
RECENT ACCOUNTING GUIDANCE	RECENT ACCOUNTING GUIDANCE Recent Accounting Standards Adopted by the Company In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-02, Leases (Topic 842). The standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. For short-term leases (those with a term of 12 months or less and that do not include a lessee purchase option that is reasonably certain to be exercised), a lessee is permitted to make (and the Company chose to utilize) an accounting policy election by asset class not to recognize ROU assets and lease liabilities, which would generally result in lease expense for these short term leases being recognized on a straight-line basis over the lease term. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted the requirements of this standard effective January 1, 2019. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, which allows lessees and lessors to recognize and measure existing leases at the beginning of the period of adoption without modifying the comparative period financial statements (which therefore will remain under prior GAAP, Topic 840, Leases). The Company elected to use the optional expedient to reflect adoption in the period of adoption (January 1, 2019) rather than the earliest period presented. The Company also elected the package of practical expedients upon transition, which includes retaining the lease classification for any leases that exist prior to adoption of the standard. The adoption of the new standard resulted in the recording of net lease assets and lease liabilities of $384,187 and $389,403 , respectively, as of January 1, 2019. The standard did not materially impact our consolidated net earnings and had no impact on cash flows. See Note 6, "Leases" for a discussion regarding leases under the new standard. In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures. In October 2018, the FASB issued ASU No. 2018-16, Derivatives and Hedging (Topic 805): Inclusion of the Secured Overnight Financing Rate ("SOFR") Overnight Index Swap ("OIS") Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. The ASU amends ASC 815 to add the OIS rate based on the SOFR as a fifth US benchmark interest rate. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements of fair value measurements under Topic 820. The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within those years. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures. In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848). The new guidance contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU No. 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the first quarter of 2020, the Company has elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The amendments in the ASU are effective for all entities as of March 12, 2020 through December 31, 2022. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur. Accounting Standards Recently Issued But Not Yet Adopted by the Company In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new guidance intends to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2022 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related disclosures.

REVENUE RECOGNITION AND ACCOUNT

REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE	REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE The Company's revenue is derived from providing quality healthcare services to its patients. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. The promise to provide quality care is accounted for as a single performance obligation satisfied at a point in time, when those services are rendered. The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans). Disaggregation of Revenue and Accounts Receivable The Company received $900 of Medicaid stimulus dollars, which related to March 2020 and is reflected in the Company's results of operations for the three month periods ended March 31, 2020 . The following table summarizes revenue from contracts with customers by payor source from continuing operations for the periods presented (dollar amounts in thousands): Three Months Ended March 31, 2020 2019 Medicaid $ 54,330 45.3 % $ 53,811 45.8 % Medicare 20,672 17.2 % 20,391 17.3 % Managed Care 12,596 10.5 % 12,998 11.1 % Private Pay and other 32,389 27.0 % 30,350 25.8 % Total $ 119,987 100.0 % $ 117,550 100.0 % Accounts receivable from continuing operations as of March 31, 2020 and December 31, 2019 are summarized in the following table: March 31, December 31, 2020 2019 Medicaid $ 23,321 $ 21,998 Medicare 9,621 11,811 Managed Care 8,052 9,103 Private Pay and other 18,461 17,609 Total accounts receivable $ 59,455 $ 60,521

LONG-TERM DEBT AND INTEREST RAT

LONG-TERM DEBT AND INTEREST RATE SWAP	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
LONG-TERM DEBT AND INTEREST RATE SWAP	LONG-TERM DEBT AND INTEREST RATE SWAP On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") with a syndicate of banks, which consists of a $80,000 mortgage loan subsequently amended ("Amended Mortgage Loan") and a $52,250 revolver subsequently amended ("Amended Revolver"). The Amended Mortgage Loan and Amended Revolver both have a five-year maturity through September 30, 2021. The Amended Mortgage Loan consists of $67,500 term and $12,500 acquisition loan facilities. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25 -year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75% , respectively. A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30,000 . The Amended Mortgage Loan balance was $58,640 as of March 31, 2020 , consisting of $49,240 on the term loan facility with an interest rate of 5.75% and $9,400 on the acquisition loan facility with an interest rate of 6.50% . The Amended Mortgage Loan is secured by fifteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions. In connection with the sale of the Kentucky Properties, the Company entered into the Sixth Amendment ("Sixth Revolver Amendment") to amend the Amended Revolver effective December 1, 2018. The Sixth Amendment decreased the Amended Revolver capacity from $52,250 to $42,250 . The Company also applied $4,947 of net proceeds from the sale of the Kentucky Properties to the outstanding borrowings under the Amended Revolver. Also effective December 1, 2018, the Company executed a Fourth Amendment (the "Fourth Term Amendment") to amend the Amended Mortgage Loan. The Company applied $11,100 and $2,100 of net proceeds from the sale of the Kentucky Properties to the Term Loan and Acquisition Loan, respectively. Additionally, we amended the Acquisition Loan availability to include a reserve of $2,100 , and therefore, our borrowing capacity is $10,400 as of March 31,2020. On April 3, 2020, the Company entered into an agreement to amend the Amended Mortgage Loan, which removes the $2,100 reserve and increases our borrowing capacity to $12,500 . See Note 13, "Subsequent Events" for further discussion on the amended debt agreement. The Company is participating in the Texas Quality Incentive Payment Program ("QIPP"). Effective May 13, 2019, the Company entered into a Fifth Amendment (the “Fifth Term Amendment”) to amend the Amended Mortgage Loan to release the operators of three of the QIPP centers in Texas from the Amended Mortgage Loan and a Seventh Amendment (the “Seventh Revolver Amendment”) to amend the Amended Revolver to remove the operators of four of the QIPP centers in Texas from the Amended Revolver and to permanently reduce the amount available under the Amended Revolver by $2,000 . At the same time, the operators of these four facilities entered into a separate revolving loan (the "affiliated revolver") with the same syndicate of banks to provide for the temporary working capital requirements of the four QIPP centers. The affiliated revolver, which is guaranteed by the Company, has an initial capacity of $5,000 , which amount is reduced by $1,000 on each of January 1, 2020, April 1, 2020 and July 1, 2020. The affiliated revolver has the same maturity date as the Amended Revolver and the Amended Mortgage Loan of September 30, 2021. The affiliated revolver is cross-defaulted with the Amended Revolver and the Amended Mortgage Loan. For further discussion of the QIPP centers in Texas, refer to Note 11, "Business Development and Other Significant Transactions." As of March 31, 2020 , the Company had $1,000 borrowings outstanding under the affiliated revolver. The interest rate related to the affiliated revolver was 5.75% as of March 31, 2020 . The balance available for borrowing under the affiliated revolver was $200 at March 31, 2020 . As of March 31, 2020 , the Company had $15,000 borrowings outstanding under the Amended Revolver compared to $15,000 outstanding as of December 31, 2019 . The interest rate related to the Amended Revolver was 5.75% as of March 31, 2020 . The outstanding borrowings on the revolver were used primarily for temporary working capital requirements. Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has four letters of credit with a total value of $12,143 outstanding as of March 31, 2020 . Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $32,108 , the balance available for borrowing under the Amended Revolver and affiliated revolver was $3,965 at March 31, 2020 . The Company’s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at March 31, 2020 . Interest Rate Swap Transaction As part of the debt agreements entered into in April 2013, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company entered into the interest rate swap agreement to mitigate the variable interest rate risk on its outstanding mortgage borrowings. The Company designated its interest rate swap as a cash flow hedge and the effective portion of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the aforementioned amendment to the Credit Agreement that occurred in February 2016, the Company retained the previously agreed upon interest rate swap modifying the terms of the swap to reflect the amended Credit Agreement. The Company redesignated the interest rate swap as a cash flow hedge. The interest rate swap agreement has a maturity date of February 26, 2021, and has an amortizing notional amount that was $26,555 as of March 31, 2020 . The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount. The applicable guidance requires companies to recognize all derivative instruments as either assets or liabilities at fair value in a company's balance sheets. The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at March 31, 2020 , the Company determined that the interest rate swap was highly effective. The interest rate swap valuation model indicated a net liability of $336 at March 31, 2020 . The fair value of the interest rate swap is included in “other current liabilities” on the Company’s interim consolidated balance sheet. The change in the interest rate swap liability is included in accumulated other comprehensive income at March 31, 2020 is $279 . As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement .

LEASES

LEASES	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
LEASES	LEASES The Company has operating and finance leases for facilities, corporate offices, and certain equipment. The Company recognizes lease expense for these operating leases on a straight-line basis over the lease term. Leases with an initial term of one year or less are not recorded on the balance sheet. The Company's other leases have original lease terms of one to twelve years, some of which include options to extend the lease for up to twenty years, and some of which include options to terminate the leases within one year. The exercise of lease renewal options is at our sole discretion. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. Upon adoption of Topic 842, the Company elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs. Leases Classification March 31, 2020 December 31, 2019 Assets Operating lease assets Operating lease right-of-use assets $ 303,754 $ 310,238 Finance lease assets Property and equipment, net (a) 856 906 Total leased assets $ 304,610 $ 311,144 Liabilities Current Operating Current portion of operating lease liabilities $ 24,529 $ 23,736 Finance Current portion of long-term debt and finance lease obligations, net 234 231 Noncurrent Operating Operating lease liabilities, less current portion 289,187 295,636 Finance Long-term debt and finance lease obligations, less current portion and deferred financing costs, net 390 445 Total lease liabilities $ 314,340 $ 320,048 (a) Finance lease assets are recorded net of accumulated amortization of $1,583 and $1,522 as of March 31, 2020 and December 31, 2019, respectively. Lease Cost of Continuing Operations Three Months Ended March 31, Classification 2020 2019 Operating lease cost (a) Lease and rent expense $ 13,512 $ 13,115 Finance lease cost: Amortization of finance lease assets Depreciation and amortization 61 67 Interest on finance lease liabilities Interest expense, net 9 11 Short term lease cost Operating expense 179 141 Net lease cost $ 13,761 $ 13,334 (a) Includes variable lease costs, which are immaterial Maturity of Lease Liabilities As of March 31, 2020 Operating Leases (a) Finance Leases (a) Total 2020 $ 51,073 $ 269 $ 51,342 2021 52,063 233 52,296 2022 53,072 136 53,208 2023 54,015 35 54,050 2024 53,898 7 53,905 After 2024 186,982 — 186,982 Total lease payments $ 451,103 $ 680 $ 451,783 Less: Interest (137,387 ) (56 ) (137,443 ) Present value of lease liabilities $ 313,716 $ 624 $ 314,340 (a) Operating and Finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised. The measurement of right-of-use assets and lease liabilities requires the Company to estimate appropriate discount rates. To the extent the rate implicit in the lease is readily determinable, such rate is utilized. However, based on information available at lease commencement for the majority of our leases, the rate implicit in the lease is not known. In these instances, the Company utilizes an incremental borrowing rate, which represents the rate of interest that it would pay to borrow on a collateralized basis over a similar term. Lease Term and Discount Rate March 31, 2020 December 31, 2019 Weighted-average remaining lease term (years) Operating leases 8.57 8.81 Finance leases 3.00 3.00 Weighted-average discount rate Operating leases 8.9% 8.9% Finance leases 6.1% 6.1% Other Information Three Months Ended March 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 12,673 $ 12,132 Operating cash flows for finance leases $ 9 $ 11 Financing cash flows for finance leases $ 52 $ 132 Acquisition of operating leases through adoption of ASC 842 $ — $ 389,403
LEASES	LEASES The Company has operating and finance leases for facilities, corporate offices, and certain equipment. The Company recognizes lease expense for these operating leases on a straight-line basis over the lease term. Leases with an initial term of one year or less are not recorded on the balance sheet. The Company's other leases have original lease terms of one to twelve years, some of which include options to extend the lease for up to twenty years, and some of which include options to terminate the leases within one year. The exercise of lease renewal options is at our sole discretion. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. Upon adoption of Topic 842, the Company elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs. Leases Classification March 31, 2020 December 31, 2019 Assets Operating lease assets Operating lease right-of-use assets $ 303,754 $ 310,238 Finance lease assets Property and equipment, net (a) 856 906 Total leased assets $ 304,610 $ 311,144 Liabilities Current Operating Current portion of operating lease liabilities $ 24,529 $ 23,736 Finance Current portion of long-term debt and finance lease obligations, net 234 231 Noncurrent Operating Operating lease liabilities, less current portion 289,187 295,636 Finance Long-term debt and finance lease obligations, less current portion and deferred financing costs, net 390 445 Total lease liabilities $ 314,340 $ 320,048 (a) Finance lease assets are recorded net of accumulated amortization of $1,583 and $1,522 as of March 31, 2020 and December 31, 2019, respectively. Lease Cost of Continuing Operations Three Months Ended March 31, Classification 2020 2019 Operating lease cost (a) Lease and rent expense $ 13,512 $ 13,115 Finance lease cost: Amortization of finance lease assets Depreciation and amortization 61 67 Interest on finance lease liabilities Interest expense, net 9 11 Short term lease cost Operating expense 179 141 Net lease cost $ 13,761 $ 13,334 (a) Includes variable lease costs, which are immaterial Maturity of Lease Liabilities As of March 31, 2020 Operating Leases (a) Finance Leases (a) Total 2020 $ 51,073 $ 269 $ 51,342 2021 52,063 233 52,296 2022 53,072 136 53,208 2023 54,015 35 54,050 2024 53,898 7 53,905 After 2024 186,982 — 186,982 Total lease payments $ 451,103 $ 680 $ 451,783 Less: Interest (137,387 ) (56 ) (137,443 ) Present value of lease liabilities $ 313,716 $ 624 $ 314,340 (a) Operating and Finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised. The measurement of right-of-use assets and lease liabilities requires the Company to estimate appropriate discount rates. To the extent the rate implicit in the lease is readily determinable, such rate is utilized. However, based on information available at lease commencement for the majority of our leases, the rate implicit in the lease is not known. In these instances, the Company utilizes an incremental borrowing rate, which represents the rate of interest that it would pay to borrow on a collateralized basis over a similar term. Lease Term and Discount Rate March 31, 2020 December 31, 2019 Weighted-average remaining lease term (years) Operating leases 8.57 8.81 Finance leases 3.00 3.00 Weighted-average discount rate Operating leases 8.9% 8.9% Finance leases 6.1% 6.1% Other Information Three Months Ended March 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 12,673 $ 12,132 Operating cash flows for finance leases $ 9 $ 11 Financing cash flows for finance leases $ 52 $ 132 Acquisition of operating leases through adoption of ASC 842 $ — $ 389,403
LEASES	LEASES The Company has operating and finance leases for facilities, corporate offices, and certain equipment. The Company recognizes lease expense for these operating leases on a straight-line basis over the lease term. Leases with an initial term of one year or less are not recorded on the balance sheet. The Company's other leases have original lease terms of one to twelve years, some of which include options to extend the lease for up to twenty years, and some of which include options to terminate the leases within one year. The exercise of lease renewal options is at our sole discretion. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. Upon adoption of Topic 842, the Company elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs. Leases Classification March 31, 2020 December 31, 2019 Assets Operating lease assets Operating lease right-of-use assets $ 303,754 $ 310,238 Finance lease assets Property and equipment, net (a) 856 906 Total leased assets $ 304,610 $ 311,144 Liabilities Current Operating Current portion of operating lease liabilities $ 24,529 $ 23,736 Finance Current portion of long-term debt and finance lease obligations, net 234 231 Noncurrent Operating Operating lease liabilities, less current portion 289,187 295,636 Finance Long-term debt and finance lease obligations, less current portion and deferred financing costs, net 390 445 Total lease liabilities $ 314,340 $ 320,048 (a) Finance lease assets are recorded net of accumulated amortization of $1,583 and $1,522 as of March 31, 2020 and December 31, 2019, respectively. Lease Cost of Continuing Operations Three Months Ended March 31, Classification 2020 2019 Operating lease cost (a) Lease and rent expense $ 13,512 $ 13,115 Finance lease cost: Amortization of finance lease assets Depreciation and amortization 61 67 Interest on finance lease liabilities Interest expense, net 9 11 Short term lease cost Operating expense 179 141 Net lease cost $ 13,761 $ 13,334 (a) Includes variable lease costs, which are immaterial Maturity of Lease Liabilities As of March 31, 2020 Operating Leases (a) Finance Leases (a) Total 2020 $ 51,073 $ 269 $ 51,342 2021 52,063 233 52,296 2022 53,072 136 53,208 2023 54,015 35 54,050 2024 53,898 7 53,905 After 2024 186,982 — 186,982 Total lease payments $ 451,103 $ 680 $ 451,783 Less: Interest (137,387 ) (56 ) (137,443 ) Present value of lease liabilities $ 313,716 $ 624 $ 314,340 (a) Operating and Finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised. The measurement of right-of-use assets and lease liabilities requires the Company to estimate appropriate discount rates. To the extent the rate implicit in the lease is readily determinable, such rate is utilized. However, based on information available at lease commencement for the majority of our leases, the rate implicit in the lease is not known. In these instances, the Company utilizes an incremental borrowing rate, which represents the rate of interest that it would pay to borrow on a collateralized basis over a similar term. Lease Term and Discount Rate March 31, 2020 December 31, 2019 Weighted-average remaining lease term (years) Operating leases 8.57 8.81 Finance leases 3.00 3.00 Weighted-average discount rate Operating leases 8.9% 8.9% Finance leases 6.1% 6.1% Other Information Three Months Ended March 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 12,673 $ 12,132 Operating cash flows for finance leases $ 9 $ 11 Financing cash flows for finance leases $ 52 $ 132 Acquisition of operating leases through adoption of ASC 842 $ — $ 389,403
LEASES	LEASES The Company has operating and finance leases for facilities, corporate offices, and certain equipment. The Company recognizes lease expense for these operating leases on a straight-line basis over the lease term. Leases with an initial term of one year or less are not recorded on the balance sheet. The Company's other leases have original lease terms of one to twelve years, some of which include options to extend the lease for up to twenty years, and some of which include options to terminate the leases within one year. The exercise of lease renewal options is at our sole discretion. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. Upon adoption of Topic 842, the Company elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs. Leases Classification March 31, 2020 December 31, 2019 Assets Operating lease assets Operating lease right-of-use assets $ 303,754 $ 310,238 Finance lease assets Property and equipment, net (a) 856 906 Total leased assets $ 304,610 $ 311,144 Liabilities Current Operating Current portion of operating lease liabilities $ 24,529 $ 23,736 Finance Current portion of long-term debt and finance lease obligations, net 234 231 Noncurrent Operating Operating lease liabilities, less current portion 289,187 295,636 Finance Long-term debt and finance lease obligations, less current portion and deferred financing costs, net 390 445 Total lease liabilities $ 314,340 $ 320,048 (a) Finance lease assets are recorded net of accumulated amortization of $1,583 and $1,522 as of March 31, 2020 and December 31, 2019, respectively. Lease Cost of Continuing Operations Three Months Ended March 31, Classification 2020 2019 Operating lease cost (a) Lease and rent expense $ 13,512 $ 13,115 Finance lease cost: Amortization of finance lease assets Depreciation and amortization 61 67 Interest on finance lease liabilities Interest expense, net 9 11 Short term lease cost Operating expense 179 141 Net lease cost $ 13,761 $ 13,334 (a) Includes variable lease costs, which are immaterial Maturity of Lease Liabilities As of March 31, 2020 Operating Leases (a) Finance Leases (a) Total 2020 $ 51,073 $ 269 $ 51,342 2021 52,063 233 52,296 2022 53,072 136 53,208 2023 54,015 35 54,050 2024 53,898 7 53,905 After 2024 186,982 — 186,982 Total lease payments $ 451,103 $ 680 $ 451,783 Less: Interest (137,387 ) (56 ) (137,443 ) Present value of lease liabilities $ 313,716 $ 624 $ 314,340 (a) Operating and Finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised. The measurement of right-of-use assets and lease liabilities requires the Company to estimate appropriate discount rates. To the extent the rate implicit in the lease is readily determinable, such rate is utilized. However, based on information available at lease commencement for the majority of our leases, the rate implicit in the lease is not known. In these instances, the Company utilizes an incremental borrowing rate, which represents the rate of interest that it would pay to borrow on a collateralized basis over a similar term. Lease Term and Discount Rate March 31, 2020 December 31, 2019 Weighted-average remaining lease term (years) Operating leases 8.57 8.81 Finance leases 3.00 3.00 Weighted-average discount rate Operating leases 8.9% 8.9% Finance leases 6.1% 6.1% Other Information Three Months Ended March 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 12,673 $ 12,132 Operating cash flows for finance leases $ 9 $ 11 Financing cash flows for finance leases $ 52 $ 132 Acquisition of operating leases through adoption of ASC 842 $ — $ 389,403

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2020
Health Care Organizations [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Professional Liability and Other Liability Insurance The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Florida, and Tennessee are now covered under the captive insurance policies along with many of the nursing centers in Alabama, Kentucky, and Texas. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least $1,000 per medical incident with a sublimit per center of $3,000 and total annual aggregate policy limits of $5,000 . All other centers within the Company's portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary. Reserve for Estimated Self-Insured Professional Liability Claims Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $26,403 and $27,390 as of March 31, 2020 and December 31, 2019 , respectively. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period. The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, the actuary has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. The actuary primarily utilizes historical data regarding the frequency and cost of the Company’s past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company’s ultimate professional liability cost for current periods. On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period. As of March 31, 2020 , the Company is engaged in 98 professional liability lawsuits. Fifteen lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs were $1,840 and $1,906 for the three months ended March 31, 2020 and 2019 , respectively. The Company follows the accounting guidance in ASC Topic 954 that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Self-insurance receivables, current portion" and "other noncurrent assets" on the Consolidated Balance Sheet. As of March 31, 2020 and December 31, 2019 there are estimated insurance recovery receivables of $1,831 and $1,011 in "Self-insurance receivables, current portion" and $155 and $1,555 in "other noncurrent assets," respectively. Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made. Civil Investigative Demand ("CID") In February 2020, we entered into a settlement agreement with the U.S. Department of Justice and the State of Tennessee of actions alleging violations of the federal False Claims Act in connection with our provision of therapy and the completion of certain resident admission forms. This settlement resolved an investigation that had begun in 2012 and covers the time period from January 1, 2010 through December 31, 2015. This agreement requires annual payments for a period of five years ending in February 2025 and also requires a contingent payment in the event the Company sells any of its owned facilities during the five-year payment period. Relative to the settlement agreement, the Company paid $500 during the first quarter of 2020, and the Company has included $1,000 and $8,000 within "Other current liabilities" and "Other noncurrent liabilities", respectively, on the Consolidated Balance Sheets. Failure to make timely any of these payments could result in rescission of the settlement and result in the government having a very large claim against us, including penalties, and/or make us ineligible to participate in certain government funded healthcare programs, any of which could in turn significantly harm our business and financial condition. In conjunction with the settlement of the government investigation related to our therapy practices, we entered into a corporate integrity agreement ("CIA") with the Office of the Inspector General of CMS. The CIA has a term of five years and imposes material burdens on the Company, its officers and directors to take actions designed to insure compliance with applicable healthcare laws, including requirements to maintain specific compliance positions within the Company, to report any non-compliance with the terms of the CIA, to return any overpayments received, to submit annual reports and for an annual audit of submitted claims by an independent review organization. The CIA sets forth penalties for non-compliance by the Company with the terms of the agreement, including possible exclusion from federally funded healthcare programs for material violations of the agreement. Other Insurance With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either a prefunded deductible policy or state-sponsored programs. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and, therefore, is completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. From the period from July 1, 2008 through March 31, 2020 , the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500 per claim, subject to an aggregate maximum of $3,000 . The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $944 and $921 at March 31, 2020 and December 31, 2019 , respectively. The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,666 and $1,575 as of March 31, 2020 and December 31, 2019 , respectively. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred. As of March 31, 2020 , the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $200 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $1,747 at March 31, 2020 . The differences between actual settlements and reserves are included in expense in the period finalized.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION Overview of Plans In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from 150 shares to 350 shares. No grants can be made under the Stock Purchase Plan after April 25, 2028. In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the 2010 Plan to increase the number of shares of our common stock authorized under the 2010 Plan from 380 shares to 680 shares. No grants can be made under the 2010 Plan after May 31, 2027. Equity Grants and Valuations During the three months ended March 31, 2020 and 2019 , the Compensation Committee of the Board of Directors approved grants totaling approximately 198 and 151 shares of restricted common stock respectively, to certain employees and members of the Board of Directors. The fair value of restricted shares is determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest one-third on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. On March 13, 2020, the Compensation Committee of the Board of Directors approved the grant of 100 shares of common stock to the Company's Chief Executive Officer, as a one-time bonus in lieu of a 2020 salary increase and as recognition for completing the settlement with the Office of the Inspector General and the disposition of all of the Company's facilities in the State of Kentucky. The stock was fully vested on the date of the grant, and the grant date fair value of which was expensed during the quarter ended March 31, 2020 . In computing the fair value estimates for options and stock-only stock appreciation rights ("SOSARs") using the Black-Scholes-Merton valuation method, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock. Upon vesting of equity awards, all restrictions are removed. Our policy is to account for forfeitures of share-based compensation awards as they occur. Summarized activity of the equity compensation plans is presented below: Weighted Options/ Average SOSARs Exercise Price Outstanding, December 31, 2019 76 $ 7.55 Granted — — Exercised — — Expired or cancelled (1 ) 5.45 Outstanding, March 31, 2020 75 $ 7.58 Exercisable, March 31, 2020 75 $ 7.58 Weighted Average Restricted Grant Date Shares Fair Value Outstanding, December 31, 2019 207 $ 5.28 Granted 198 2.00 Vested (188 ) 3.93 Cancelled (19 ) 4.93 Outstanding, March 31, 2020 198 $ 3.32 Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows: Weighted Average Restricted Grant Date Share Units Fair Value Outstanding, December 31, 2019 48 $ 5.08 Granted 29 2.00 Vested (13 ) 8.11 Outstanding, March 31, 2020 64 $ 3.05 The SOSARs and Options were valued and recorded in the same manner, and, other than amounts that may be settled pursuant to employment agreements with certain members of management, will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model. The following table summarizes information regarding stock options and SOSAR grants outstanding as of March 31, 2020 : Weighted Average Intrinsic Intrinsic Range of Exercise Grants Value-Grants Grants Value-Grants Exercise Prices Prices Outstanding Outstanding Exercisable Exercisable $8.14 to $10.21 $ 8.83 45 $ — 45 $ — $5.45 to $5.86 $ 5.72 30 $ — 30 $ — 75 75 Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $338 and $140 in the three month periods ended March 31, 2020 and 2019 , respectively.

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company recorded an income tax benefit from continuing operations of $104 during the three months ended March 31, 2020 and a benefit of $1,028 during the three months ended March 31, 2019 . When assessing the recoverability of the Company’s recorded deferred tax assets, the accounting guidance, ASC 740, Income Taxes , requires that all available positive and negative evidence be considered in evaluating the likelihood that the Company will be able to realize the benefit of its deferred tax assets in the future, which is highly judgmental. Such evidence includes, but may not be limited to, scheduled reversals of deferred tax assets and liabilities, projected future taxable income, tax-planning strategies, and the results of recent operations. When assessing all available evidence, the Company recognized that governmental and regulatory changes have put downward revenue pressure on the long-term care industry as a piece of negative evidence in its analysis. In 2019 and 2018 combined, the Company recognized a total expense of $9.5 million related to the CID settlement in principle. Additionally, in 2017 it recorded an additional $5.5 million of income tax expense related to the revaluation of deferred tax assets in accordance with the Tax Cuts and Jobs Act. Because of these items and other financial results, the Company entered a cumulative loss for the 36 preceding months ended June 30, 2019 and performed a thorough assessment of the available positive and negative evidence in order to ascertain whether it is more likely than not that in future periods the Company will generate sufficient pre-tax income to utilize all of its federal deferred tax assets and its net operating loss and other carryforwards and credits. The Company also identified several pieces of positive evidence that were considered and weighed in the analysis performed regarding the valuation of deferred tax assets. The evidence included the termination of operations for 10 nursing facilities in Kentucky completed in the third quarter of 2019, the related corporate and regional restructuring and other cost saving initiatives already in process. The evidence also included consideration of participation in revenue incentive programs that are expected to generate additional revenue, the long-term expiration dates of a majority of the net operating losses and credits, and the Company’s history of not having carryforwards or credits expire unutilized. In performing the analysis, the Company contemplated utilization of the recorded deferred tax assets under multiple scenarios. After consideration of these factors, the Company determined that a full valuation allowance of $20.0 million was necessary as of June 30, 2019. As of March 31, 2020 , the Company has a valuation allowance in the amount of $21.5 million . The Company will continue to periodically assess the realizability of its future deferred tax assets. On March 27, 2020, the CARES Act was enacted and signed into law. Certain provisions of the CARES Act impact the 2019 income tax provision computations of the Company and are reflected in the first quarter of 2020, or the period of enactment. The CARES Act contains modifications on the depreciation of qualified improvement property, as well as the limitation of business interest for tax years beginning in 2019 and 2020. The new life classification of the qualified improvement property, allowing for bonus depreciation to be taken, along with the modification to Section 163(j) to increase the allowable business interest deduction from 30% of adjusted taxable income to 50% of adjusted taxable income significantly increased the allowable deductions of the Company and result in additional taxable losses for the year-ended 2019, resulting in greater net operating losses (“NOL”) to be carried back. The NOL carryback resulted in a tax refund of $321 and an increase to the Work Opportunity Tax Credit (“WOTC”) deferred tax asset, which is offset by a full valuation allowance. These changes pursuant to the CARES Act did not have a significant impact to the first quarter of 2020, other than the tax refund and net adjustments to the WOTC credit and NOL deferred tax assets, which are offset by a valuation allowance. As a result of the CARES Act, it is anticipated that the Company will fully utilize all interest expense expected to be incurred in 2020. The Company is not currently under examination by any major income tax jurisdiction. During 2020, the statutes of limitations will lapse on the Company's 2016 Federal tax year and certain 2015 and 2016 state tax years. The Company does not believe the Federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the Interim Financial Statements for the three months ended March 31, 2020 and 2019 .

EARNINGS PER COMMON SHARE

EARNINGS PER COMMON SHARE	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
EARNINGS PER COMMON SHARE	EARNINGS PER COMMON SHARE Information with respect to basic and diluted net loss per common share is presented below in thousands, except per share: Three Months Ended March 31, 2020 2019 Net loss Loss from continuing operations $ (510 ) $ (1,574 ) Loss from discontinued operations, net of income taxes (243 ) (1,772 ) Net loss $ (753 ) $ (3,346 ) Three Months Ended March 31, 2020 2019 Net loss per common share: Per common share – basic Loss from continuing operations $ (0.08 ) $ (0.24 ) Loss from discontinued operations (0.04 ) (0.28 ) Net loss per common share – basic $ (0.12 ) $ (0.52 ) Per common share – diluted Loss from continuing operations $ (0.08 ) $ (0.24 ) Loss from discontinued operations (0.04 ) (0.28 ) Net loss per common share – diluted $ (0.12 ) $ (0.52 ) Weighted Average Common Shares Outstanding: Basic 6,506 6,424 Diluted 6,506 6,424 The effects of 75 and 99 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the three months ended March 31, 2020 and 2019 , respectively, because these securities would have been anti-dilutive.

BUSINESS DEVELOPMENTS AND OTHER

BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS	3 Months Ended
	Mar. 31, 2020
Business Combinations [Abstract]
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS	BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS 2018 New Master Lease Agreement On October 1, 2018, the Company entered into a new Master Lease Agreement (the "Lease") with Omega Healthcare Investors (the "Lessor") to lease 34 centers currently owned by the Lessor and operated by Diversicare. The old Master Lease with the Lessor provided for its operation of 23 skilled nursing centers in Texas, Kentucky, Alabama, Tennessee, Florida, and Ohio. Additionally, Diversicare operated 11 centers owned by the Lessor under separate leases in Missouri, Kentucky, Indiana, and Ohio. The Lease entered into by Diversicare and the Lessor consolidated the leases for all 34 centers under one new Master Lease. The Lease has an initial term of twelve years with two optional 10 -year extensions. The Lease has a common date of annual lease fixed escalators of 2.15% beginning on October 1, 2019. On August 30, 2019, the Company terminated operations of ten centers in Kentucky and concurrently transferred operations to a new operator. The agreement effectively amended the Lease with Omega Healthcare Investors to remove the ten Kentucky facilities, reduce the annual rent expense, and release the Company from any further obligations arising under the Lease with respect to the Kentucky facilities. The remaining Lease terms are unchanged with an initial term of twelve years and two optional 10 -year extensions. The annual lease fixed escalator remains at 2.15% beginning on October 1, 2019. Quality Incentive Payment Program The Company recently expanded its participation in QIPP as administered by the Texas Health and Human Services Commission. QIPP provides supplemental Medicaid payments for skilled nursing centers that achieve certain quality measures. The Company previously had one of its Texas skilled nursing centers participating in the QIPP. During April 2019, the Company enrolled an additional eleven of its Texas skilled nursing centers in the program, such that twelve of the Company’s centers participate in the QIPP effective September 1, 2019. To allow four of these centers to meet the QIPP participation requirements, the Company entered into a transaction with a Texas medical district already participating in the QIPP, providing for the transfer of the provider license from the Company to the medical district. The Company’s operating subsidiary retained the management of the centers on behalf of the medical district.

DISCONTINUED OPERATIONS (Notes)

DISCONTINUED OPERATIONS (Notes)	3 Months Ended
	Mar. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	DISCONTINUED OPERATIONS Kentucky Disposition On October 30, 2018 the Company entered into an Asset Purchase Agreement (the "Agreement") with Fulton Nursing and Rehabilitation, LLC, Holiday Fulton Propco LLC, Birchwood Nursing and Rehabilitation LLC, Padgett Clinton Propco LLC, Westwood Nursing and Rehabilitation LLC, and Westwood Glasgow Propco (the "Buyers") to sell the assets and transfer the operations of the Kentucky Properties. On December 1, 2018, the Company completed the sale of the Kentucky Properties with the Buyers for a purchase price of $18,700 . This transaction did not meet the accounting criteria to be reported as a discontinued operation. The carrying value of these centers' assets was $13,331 , resulting in a gain of $4,825 , with remaining proceeds for miscellaneous closing costs. The proceeds were used to relieve debt, which is required under the terms of the Company's Amended Mortgage Loan and Amended Revolver. Refer to Note 5, "Long-term Debt and Interest Rate Swap" for more information on this transaction. On May 22, 2019, the Company announced that it entered into an agreement with Omega to amend its master lease to terminate operations of ten nursing facilities, totaling approximately 885 skilled nursing beds, located in Kentucky and to concurrently transfer operations to an operator selected by Omega. On August 30, 2019, the Company completed the transaction and no longer operates any skilled nursing centers in the State of Kentucky. The Company's exit from the state represents a strategic shift that has (or will have) a major effect on the Company's operations and financial results. In accordance with ASC 205, the Company's discontinued financial position, results of operations and cash flows have been reclassified on the face of the financial statements and footnotes for all periods presented to reflect the discontinued status of these operations. The transaction resulted in a gain on the modification of the Omega lease, which is presented within Discontinued Operations on the Consolidated Statements of Operations for the third quarter of 2019. The net gain on the transaction was $733 . These centers contributed revenues of $16,803 for the three months ended March 31, 2019 and net loss of $243 and $1,772 for the three months ended March 31, 2020 and 2019 , respectively. The net loss for the nursing centers included in discontinued operations does not reflect any allocation of corporate general and administrative expense. The Company considered these additional costs along with the centers' future prospects based upon operating history when determining the contribution of the skilled nursing centers to its operations. The Company did not transfer the accounts receivable or liabilities, inclusive of the reserves for professional liability and workers' compensation, to the new operator. The Company expects to collect the balance of the accounts receivable and pay the remaining liabilities in the ordinary course of business through its future operating cash flows.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS COVID-19 On March 27, 2020, the U.S. government enacted the CARES Act to provide relief during the COVID-19 pandemic. The CARES Act authorized $100 billion in funding to healthcare entities to be distributed through the Public Health and Social Services Emergency Fund ("PHSSEF"). Payments from PHSSEF are intended to compensate providers for lost revenues and healthcare-related expenses attributable to the COVID-19 pandemic. These payments are not required to be repaid, provided the recipients attest to and comply with certain terms and conditions, including not using PHSSEF funds to reimburse expenses or losses that other sources are obligated to reimburse. The Company will utilize these funds to pay for COVID-19 related expenses that includes but is not limited to increased wages and increased costs for personal protective equipment and other supplies. In April, the Company received approximately $9,000 of Medicare stimulus funds and is expecting to receive an additional $700 in the second quarter of 2020. Additionally, the Families First Coronavirus Response Act provided states with a temporary increase in the regular federal matching rate, or federal medical assistance percentage, used to determine the federal government's share of the cost of covered services in state Medicaid programs, provided the states agreed to certain conditions such as not imposing cost-sharing requirements for COVID-19-related testing and treatment. The Company received $900 of Medicaid dollars related to this temporary increase in the federal matching rate, which related to March 2020 and is reflected in "patient revenues, net" in the Company's results of operations for the three month period ended March 31, 2020 . Also, the Company has elected to participate in the payment deferral of employer payroll taxes during 2020. Additional emergency appropriations are being made available to eligible providers under the Paycheck Protection Program and Health Care Enhancement Act ("PPPHCE Act"), which was enacted on April 24, 2020. These funds will be distributed through the PHSSEF. Recipients will not be required to repay the government for funds received, provided they comply with terms and conditions, which have not yet been finalized. Since the end of the quarter, there have been additional cases of COVID-19 at certain of the Company's centers. The Company has continued to experience reduced occupancy and increased operating expenses at its centers in the form or increased wages and increased cost for personal protective equipment, food and certain other supplies. The Company expects such increased expenses to continue and likely increase further during the remainder of 2020. Debt Amendment Effective April 3, 2020, the Company entered into a Seventh Amendment ("Seventh Amendment") to amend the Amended Mortgage Loan, a Ninth Amendment ("Ninth Amendment") to amend the Amended Revolver and a Second Amendment ("Second Amendment") to the affiliated revolver. The Seventh Amendment removes the reserve of $2,100 on the Acquisition Loan availability, and therefore, our borrowing capacity is now $12,500 . The Ninth Amendment and Second Amendment increases the eligible days of qualifying accounts receivable from 120 days to 150 days for the purposes of calculating our borrowing capacity on the revolvers. The new LIBOR base rate is 0.5% .

CONSOLIDATION AND BASIS OF PR_2

CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting	The interim consolidated financial statements for the three month periods ended March 31, 2020 and 2019 , included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at March 31, 2020 , and the results of operations, and changes in shareholders' deficit and cash flows for the three month periods ended March 31, 2020 and 2019 . The Company’s balance sheet information at December 31, 2019 , was derived from its audited consolidated financial statements as of December 31, 2019 . Effective January 1, 2019, we adopted the requirements of Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842), as discussed in Notes 3 and 6 to the interim consolidated financial statements. All amounts and disclosures set forth in these financial statements comply with the new standard. The results of operations for the periods ended March 31, 2020 and 2019 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 .
Discontinued Operations	In accordance with ASC 205, the Company's discontinued operating results have been reclassified on the face of the financial statements and footnotes for all periods presented to reflect the discontinued status of these operations.
Recent Accounting Standards Adopted and Not Adopted by the Company	Recent Accounting Standards Adopted by the Company In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-02, Leases (Topic 842). The standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. For short-term leases (those with a term of 12 months or less and that do not include a lessee purchase option that is reasonably certain to be exercised), a lessee is permitted to make (and the Company chose to utilize) an accounting policy election by asset class not to recognize ROU assets and lease liabilities, which would generally result in lease expense for these short term leases being recognized on a straight-line basis over the lease term. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted the requirements of this standard effective January 1, 2019. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, which allows lessees and lessors to recognize and measure existing leases at the beginning of the period of adoption without modifying the comparative period financial statements (which therefore will remain under prior GAAP, Topic 840, Leases). The Company elected to use the optional expedient to reflect adoption in the period of adoption (January 1, 2019) rather than the earliest period presented. The Company also elected the package of practical expedients upon transition, which includes retaining the lease classification for any leases that exist prior to adoption of the standard. The adoption of the new standard resulted in the recording of net lease assets and lease liabilities of $384,187 and $389,403 , respectively, as of January 1, 2019. The standard did not materially impact our consolidated net earnings and had no impact on cash flows. See Note 6, "Leases" for a discussion regarding leases under the new standard. In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures. In October 2018, the FASB issued ASU No. 2018-16, Derivatives and Hedging (Topic 805): Inclusion of the Secured Overnight Financing Rate ("SOFR") Overnight Index Swap ("OIS") Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. The ASU amends ASC 815 to add the OIS rate based on the SOFR as a fifth US benchmark interest rate. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements of fair value measurements under Topic 820. The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within those years. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures. In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848). The new guidance contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU No. 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the first quarter of 2020, the Company has elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The amendments in the ASU are effective for all entities as of March 12, 2020 through December 31, 2022. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur. Accounting Standards Recently Issued But Not Yet Adopted by the Company In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new guidance intends to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2022 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related disclosures.
Revenue Recognition	The Company's revenue is derived from providing quality healthcare services to its patients. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. The promise to provide quality care is accounted for as a single performance obligation satisfied at a point in time, when those services are rendered. The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).

REVENUE RECOGNITION AND ACCOU_2

REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE (Tables)	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table summarizes revenue from contracts with customers by payor source from continuing operations for the periods presented (dollar amounts in thousands): Three Months Ended March 31, 2020 2019 Medicaid $ 54,330 45.3 % $ 53,811 45.8 % Medicare 20,672 17.2 % 20,391 17.3 % Managed Care 12,596 10.5 % 12,998 11.1 % Private Pay and other 32,389 27.0 % 30,350 25.8 % Total $ 119,987 100.0 % $ 117,550 100.0 %
Schedule of Accounts Receivable	Accounts receivable from continuing operations as of March 31, 2020 and December 31, 2019 are summarized in the following table: March 31, December 31, 2020 2019 Medicaid $ 23,321 $ 21,998 Medicare 9,621 11,811 Managed Care 8,052 9,103 Private Pay and other 18,461 17,609 Total accounts receivable $ 59,455 $ 60,521

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Assets and Liabilities, Leases	Leases Classification March 31, 2020 December 31, 2019 Assets Operating lease assets Operating lease right-of-use assets $ 303,754 $ 310,238 Finance lease assets Property and equipment, net (a) 856 906 Total leased assets $ 304,610 $ 311,144 Liabilities Current Operating Current portion of operating lease liabilities $ 24,529 $ 23,736 Finance Current portion of long-term debt and finance lease obligations, net 234 231 Noncurrent Operating Operating lease liabilities, less current portion 289,187 295,636 Finance Long-term debt and finance lease obligations, less current portion and deferred financing costs, net 390 445 Total lease liabilities $ 314,340 $ 320,048 (a) Finance lease assets are recorded net of accumulated amortization of $1,583 and $1,522 as of March 31, 2020 and December 31, 2019, respectively.
Lease, Cost	Lease Cost of Continuing Operations Three Months Ended March 31, Classification 2020 2019 Operating lease cost (a) Lease and rent expense $ 13,512 $ 13,115 Finance lease cost: Amortization of finance lease assets Depreciation and amortization 61 67 Interest on finance lease liabilities Interest expense, net 9 11 Short term lease cost Operating expense 179 141 Net lease cost $ 13,761 $ 13,334 (a) Includes variable lease costs, which are immaterial
Lessee, Operating Lease, Liability, Maturity	Maturity of Lease Liabilities As of March 31, 2020 Operating Leases (a) Finance Leases (a) Total 2020 $ 51,073 $ 269 $ 51,342 2021 52,063 233 52,296 2022 53,072 136 53,208 2023 54,015 35 54,050 2024 53,898 7 53,905 After 2024 186,982 — 186,982 Total lease payments $ 451,103 $ 680 $ 451,783 Less: Interest (137,387 ) (56 ) (137,443 ) Present value of lease liabilities $ 313,716 $ 624 $ 314,340 (a) Operating and Finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised.
Finance Lease, Liability, Maturity	Maturity of Lease Liabilities As of March 31, 2020 Operating Leases (a) Finance Leases (a) Total 2020 $ 51,073 $ 269 $ 51,342 2021 52,063 233 52,296 2022 53,072 136 53,208 2023 54,015 35 54,050 2024 53,898 7 53,905 After 2024 186,982 — 186,982 Total lease payments $ 451,103 $ 680 $ 451,783 Less: Interest (137,387 ) (56 ) (137,443 ) Present value of lease liabilities $ 313,716 $ 624 $ 314,340 (a) Operating and Finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised.
Summary of Other Lease Information	Lease Term and Discount Rate March 31, 2020 December 31, 2019 Weighted-average remaining lease term (years) Operating leases 8.57 8.81 Finance leases 3.00 3.00 Weighted-average discount rate Operating leases 8.9% 8.9% Finance leases 6.1% 6.1% Other Information Three Months Ended March 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 12,673 $ 12,132 Operating cash flows for finance leases $ 9 $ 11 Financing cash flows for finance leases $ 52 $ 132 Acquisition of operating leases through adoption of ASC 842 $ — $ 389,403

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Summarized activity of equity compensation plans	Summarized activity of the equity compensation plans is presented below: Weighted Options/ Average SOSARs Exercise Price Outstanding, December 31, 2019 76 $ 7.55 Granted — — Exercised — — Expired or cancelled (1 ) 5.45 Outstanding, March 31, 2020 75 $ 7.58 Exercisable, March 31, 2020 75 $ 7.58
Schedule of summarized activity of Restricted Share Units	Weighted Average Restricted Grant Date Shares Fair Value Outstanding, December 31, 2019 207 $ 5.28 Granted 198 2.00 Vested (188 ) 3.93 Cancelled (19 ) 4.93 Outstanding, March 31, 2020 198 $ 3.32 Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows: Weighted Average Restricted Grant Date Share Units Fair Value Outstanding, December 31, 2019 48 $ 5.08 Granted 29 2.00 Vested (13 ) 8.11 Outstanding, March 31, 2020 64 $ 3.05
Schedule of summarized information regarding stock options and SOSAR grants outstanding	The following table summarizes information regarding stock options and SOSAR grants outstanding as of March 31, 2020 : Weighted Average Intrinsic Intrinsic Range of Exercise Grants Value-Grants Grants Value-Grants Exercise Prices Prices Outstanding Outstanding Exercisable Exercisable $8.14 to $10.21 $ 8.83 45 $ — 45 $ — $5.45 to $5.86 $ 5.72 30 $ — 30 $ — 75 75

EARNINGS PER COMMON SHARE (Tabl

EARNINGS PER COMMON SHARE (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Basic and diluted net income (loss) per common share	Information with respect to basic and diluted net loss per common share is presented below in thousands, except per share: Three Months Ended March 31, 2020 2019 Net loss Loss from continuing operations $ (510 ) $ (1,574 ) Loss from discontinued operations, net of income taxes (243 ) (1,772 ) Net loss $ (753 ) $ (3,346 ) Three Months Ended March 31, 2020 2019 Net loss per common share: Per common share – basic Loss from continuing operations $ (0.08 ) $ (0.24 ) Loss from discontinued operations (0.04 ) (0.28 ) Net loss per common share – basic $ (0.12 ) $ (0.52 ) Per common share – diluted Loss from continuing operations $ (0.08 ) $ (0.24 ) Loss from discontinued operations (0.04 ) (0.28 ) Net loss per common share – diluted $ (0.12 ) $ (0.52 ) Weighted Average Common Shares Outstanding: Basic 6,506 6,424 Diluted 6,506 6,424

BUSINESS (Details)

BUSINESS (Details)	Mar. 31, 2020statecenterbed	Oct. 01, 2018center
Accounting Policies [Line Items]
Number of states in which entity operates | state	9
Number of nursing centers | center	62
Number of licensed nursing beds	7,329
Number of nursing center facilities owned | center	15
Number of nursing center facilities leased | center	47	34
Number of licensed assisted and residential living beds	397
Minimum
Accounting Policies [Line Items]
Number of licensed nursing beds per center	50
Maximum
Accounting Policies [Line Items]
Number of licensed nursing beds per center	320

CONSOLIDATION AND BASIS OF PR_3

CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Details) $ in Thousands	Dec. 01, 2018USD ($)property	Mar. 31, 2020facility	Aug. 30, 2019facility
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of nursing center facilities terminated		10
Kentucky Properties
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | property	3
Proceeds from sale of assets | $	$ 18,700
Kentucky Properties | Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of nursing center facilities terminated			10

RECENT ACCOUNTING GUIDANCE (Det

RECENT ACCOUNTING GUIDANCE (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Jan. 01, 2019
Accounting Policies [Abstract]
Net lease assets	$ 304,610	$ 311,144	$ 384,187
Lease liabilities	$ 314,340	$ 320,048	$ 389,403

REVENUE RECOGNITION AND ACCOU_3

REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Apr. 30, 2020	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Total revenues		$ 119,987	$ 117,550
Total revenues, as a percent		100.00%	100.00%
Medicaid
Disaggregation of Revenue [Line Items]
Total revenues		$ 54,330	$ 53,811
Total revenues, as a percent		45.30%	45.80%
Medicare
Disaggregation of Revenue [Line Items]
Total revenues		$ 20,672	$ 20,391
Total revenues, as a percent		17.20%	17.30%
Managed Care
Disaggregation of Revenue [Line Items]
Total revenues		$ 12,596	$ 12,998
Total revenues, as a percent		10.50%	11.10%
Private Pay and other
Disaggregation of Revenue [Line Items]
Total revenues		$ 32,389	$ 30,350
Total revenues, as a percent		27.00%	25.80%
Subsequent Event
Disaggregation of Revenue [Line Items]
CARES, Medicare related to rate received	$ 900

REVENUE RECOGNITION AND ACCOU_4

REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE - Summary of Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	$ 59,455	$ 60,521
Medicaid
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	23,321	21,998
Medicare
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	9,621	11,811
Managed Care
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	8,052	9,103
Private Pay and other
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	$ 18,461	$ 17,609

LONG-TERM DEBT AND INTEREST R_2

LONG-TERM DEBT AND INTEREST RATE SWAP (Details)	Apr. 03, 2020USD ($)	Dec. 01, 2018USD ($)	Feb. 26, 2016USD ($)center	Mar. 31, 2020USD ($)letter_of_credit	Dec. 31, 2019USD ($)	Sep. 01, 2019center	May 13, 2019USD ($)center	Apr. 30, 2019center	Mar. 31, 2019center	Jun. 30, 2017USD ($)	Oct. 03, 2016USD ($)
Line of Credit Facility [Line Items]
Number of QIPP centers released | center							3
Number of skilled nursing centers participating in QIPP | center						12	4	11	1
Accumulated other comprehensive income (loss)				$ 289,000	$ 568,000
Interest rate swap
Line of Credit Facility [Line Items]
Notional amount of interest rate derivatives				$ 26,555,000
Annual fixed rate (as a percent)				5.79%
Net asset based on interest rate swap valuation model				$ 336,000
Accumulated other comprehensive income (loss)				$ 279,000
Amended and restated credit agreement
Line of Credit Facility [Line Items]
Number of letters of credit | letter_of_credit				4
Mortgage loan | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity			$ 80,000,000
Term of agreements			5 years
Period of amortization			25 years
Amended mortgage loan balance				$ 58,640,000
Number of owned nursing centers to secure Amended Mortgage Loan | center			15
Mortgage loan | Amended and restated credit agreement | Interest rate swap
Line of Credit Facility [Line Items]
Debt interest rate at period end			5.79%
Amended revolver | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity		$ 42,250,000		$ 32,108,000			$ 5,000,000			$ 52,250,000	$ 52,250,000
Repayments of lines of credit		4,947,000
Reduction in credit facility							2,000,000
Interest rate during period				5.75%
Borrowings outstanding				$ 15,000,000	$ 15,000,000
Amended revolver | Amended and restated credit agreement | LIBOR
Line of Credit Facility [Line Items]
Interest rate percentage			4.00%
Amended revolver | Affiliated Revolving Credit Agreement
Line of Credit Facility [Line Items]
Periodic reduction in capacity							$ 1,000,000
Balance available for borrowing under revolving credit center				1,000,000
Borrowings outstanding				200,000
Amended revolver | Amended Revolver and Affiliated Revolver
Line of Credit Facility [Line Items]
Balance available for borrowing under revolving credit center				$ 3,965,000
Letter of credit | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Annual fees for letters of credit issued under Revolver (as a percentage)			3.00%
Mortgage term loan | Mortgage loan | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity			$ 67,500,000
Debt interest rate at period end				5.75%
Amended mortgage loan balance				$ 49,240,000
Mortgage term loan | Mortgage loan | Amended and restated credit agreement | Interest rate swap | Designated as hedging instrument
Line of Credit Facility [Line Items]
Notional amount of interest rate derivatives			$ 30,000,000
Mortgage term loan | Mortgage loan | Amended and restated credit agreement | LIBOR
Line of Credit Facility [Line Items]
Interest rate percentage			4.00%
Mortgage term loan | Amended revolver | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Repayments of lines of credit		11,100,000
Acquisition loan facility | Mortgage loan | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity			$ 12,500,000
Debt interest rate at period end				6.50%
Amended mortgage loan balance				$ 9,400,000
Acquisition loan facility | Mortgage loan | Amended and restated credit agreement | LIBOR
Line of Credit Facility [Line Items]
Interest rate percentage			4.75%
Acquisition loan facility | Amended revolver | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity		10,400,000
Repayments of lines of credit		$ 2,100,000
Omega Healthcare Investors Inc | Amended revolver | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Letters of credit security deposit for a lease				$ 12,143,000
Subsequent Event | Amended revolver | Amended and restated credit agreement | LIBOR
Line of Credit Facility [Line Items]
Interest rate percentage	0.50%
Subsequent Event | Acquisition loan facility | Amended revolver | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity	$ 12,500,000

LEASES - Narrative (Details)

LEASES - Narrative (Details)	3 Months Ended
	Mar. 31, 2020
Lessee, Lease, Description [Line Items]
Other leases renewal term	20 years
Other leases termination period	1 year
Minimum
Lessee, Lease, Description [Line Items]
Other leases remaining lease term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Other leases remaining lease term	12 years

LEASES - Balance Sheet Classifi

LEASES - Balance Sheet Classification (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Jan. 01, 2019
Assets:
Operating lease right-of-use assets	$ 303,754		$ 310,238
Finance lease assets	856		906
Total leased assets	304,610		311,144	$ 384,187
Liabilities, Current [Abstract]
Current portion of operating lease liabilities	24,529		23,736
Finance lease, current	234		231
Liabilities, Noncurrent [Abstract]
Operating lease liabilities, less current portion	289,187		295,636
Finance lease, noncurrent	390		445
Total lease liabilities	314,340		$ 320,048	$ 389,403
Accumulated amortization of finance leases	$ 1,583	$ 1,522

LEASES - Lease Cost (Details)

LEASES - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Operating lease cost	$ 13,512	$ 13,115
Amortization of finance lease assets	61	67
Interest on finance lease liabilities	9	11
Short term lease cost	179	141
Net lease cost	$ 13,761	$ 13,334

LEASES - Maturities of Operatin

LEASES - Maturities of Operating and Financing Lease Liabilities (Details) $ in Thousands	Mar. 31, 2020USD ($)
Operating Leases
2020	$ 51,073
2021	52,063
2022	53,072
2023	54,015
2024	53,898
After 2024	186,982
Total lease payments	451,103
Less: Interest	(137,387)
Present value of lease liabilities	313,716
Finance Leases
2020	269
2021	233
2022	136
2023	35
2024	7
After 2024	0
Total lease payments	680
Less: Interest	(56)
Present value of lease liabilities	624
Operating and Finance Lease Liabilities Payments Due [Abstract]
2020	51,342
2021	52,296
2022	53,208
2023	54,050
2024	53,905
After 2024	186,982
Total lease payments	451,783
Less: Interest	(137,443)
Present value of lease liabilities	$ 314,340

LEASES - Other Lease Informatio

LEASES - Other Lease Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Weighted-average remaining lease term (years)
Operating leases	8 years 6 months 26 days		8 years 9 months 22 days
Finance leases	3 years		3 years
Weighted-average discount rate
Operating leases	8.90%		8.90%
Finance leases	6.10%		6.10%
Operating cash flows for operating leases	$ 12,673	$ 12,132
Operating cash flows for finance leases	9	11
Financing cash flows for finance leases	52	132
Acquisition of operating leases though adoption of ASC 842	$ 0	$ 389,403

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details)	3 Months Ended
	Mar. 31, 2020USD ($)lawsuit	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)
Malpractice Insurance [Line Items]
Number of professional liability lawsuits | lawsuit	98
Cash expenditures for self-insured professional liability costs	$ 1,840,000	$ 1,906,000
Other Insurance
Liability for workers compensation claims	944,000		$ 921,000
Workers compensation insurance, non current receivable for excess premiums paid	1,666,000		1,575,000
Professional malpractice liability insurance
Malpractice Insurance [Line Items]
Liability for reported and estimated future claims	26,403,000		27,390,000
Prefunded deductible policy
Malpractice Insurance [Line Items]
Insurance policy coverage limits per claim	500,000
Other Insurance
Insurance policy coverage limits per claim	500,000
Professional liability insurance, annual coverage limit per facility	3,000,000
Health insurance, maximum self-insured annual amount per individual	200,000
Liability for reported claims and estimates for incurred but unreported claims	1,747,000
SHC Risk Carriers, Inc | Professional malpractice liability insurance
Malpractice Insurance [Line Items]
Insurance policy coverage limits per claim	1,000,000
Malpractice insurance annual sublimit per center	3,000,000
Aggregate policy limit	5,000,000
Other Insurance
Insurance policy coverage limits per claim	$ 1,000,000
Scheduled for trial or arbitration over next 12 months
Malpractice Insurance [Line Items]
Number of professional liability lawsuits | lawsuit	15
Civil Investigative Demand
Malpractice Insurance [Line Items]
Settlement payment period	5 years
Payments made during period	$ 500,000
Current loss accrual	1,000,000
Noncurrent loss accrual	8,000,000
Self Insurance Receivable, Current
Malpractice Insurance [Line Items]
Estimated insurance recovery receivables	1,831,000		1,011,000
Other Noncurrent Assets
Malpractice Insurance [Line Items]
Estimated insurance recovery receivables	$ 155,000		$ 1,555,000

STOCK-BASED COMPENSATION - Nar

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ in Thousands	Mar. 13, 2020	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2017	May 31, 2017	Jun. 30, 2016	May 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense		$ 338	$ 140
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant of restricted common stock (shares)		198,000	151,000
Restricted Stock | First anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards		33.33%
Restricted Stock | Second anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards		33.33%
Restricted Stock | Third anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards		33.33%
2008 Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of quoted market price offering rate		85.00%
Restriction period		2 years
Shares authorized under the plan (shares)						350,000	150,000
2010 Long Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (shares)				680,000	380,000
Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock granted to CEO (in shares)	100,000

STOCK-BASED COMPENSATION - Sch

STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) - Stock Options and Stock Appreciation Rights (SARs) shares in Thousands	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Number of Shares
Outstanding, beginning (shares) | shares	76
Granted (shares) | shares	0
Exercised (shares) | shares	0
Expired or cancelled (shares) | shares	(1)
Outstanding, ending (shares) | shares	75
Exercisable (shares) | shares	75
Weighted Average Exercise Price
Outstanding, beginning (dollars per share) | $ / shares	$ 7.55
Granted (dollars per share) | $ / shares	0
Exercised (dollars per share) | $ / shares	0
Expired or cancelled (dollars per share) | $ / shares	5.45
Outstanding, ending (dollars per share) | $ / shares	7.58
Exercisable, weighted average exercise price (dollars per share) | $ / shares	$ 7.58

STOCK-BASED COMPENSATION - S_2

STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details) - $ / shares shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Restricted Shares
Number of Shares
Outstanding, beginning (shares)	207
Granted (shares)	198	151
Vested (shares)	(188)
Cancelled (shares)	(19)
Outstanding, ending (shares)	198
Weighted Average Granted Date Fair Value
Outstanding, beginning (dollars per share)	$ 5.28
Granted (dollars per share)	2
Vested (dollars per share)	3.93
Cancelled (dollars per share)	4.93
Outstanding, ending (dollars per share)	$ 3.32
Restricted Stock Units (RSUs)
Number of Shares
Outstanding, beginning (shares)	48
Granted (shares)	29
Vested (shares)	(13)
Outstanding, ending (shares)	64
Weighted Average Granted Date Fair Value
Outstanding, beginning (dollars per share)	$ 5.08
Granted (dollars per share)	2
Vested (dollars per share)	8.11
Outstanding, ending (dollars per share)	$ 3.05

STOCK-BASED COMPENSATION - S_3

STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details) - Stock Options and Stock Appreciation Rights (SARs) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise prices (dollars per share)	$ 7.58	$ 7.55
Grants outstanding (shares)	75
Grants exercisable (shares)	75
$8.14 to $10.21
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices, minimum (dollars per share)	$ 8.14
Range of exercise prices, maximum (dollars per share)	10.21
Weighted average exercise prices (dollars per share)	$ 8.83
Grants outstanding (shares)	45
Intrinsic value - grants outstanding	$ 0
Grants exercisable (shares)	45
Intrinsic value - grants exercisable	$ 0
$5.45 to $5.86
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices, minimum (dollars per share)	$ 5.45
Range of exercise prices, maximum (dollars per share)	5.86
Weighted average exercise prices (dollars per share)	$ 5.72
Grants outstanding (shares)	30
Intrinsic value - grants outstanding	$ 0
Grants exercisable (shares)	30
Intrinsic value - grants exercisable	$ 0

INCOME TAXES (Details)

INCOME TAXES (Details) $ in Thousands	Mar. 27, 2020USD ($)	Mar. 31, 2020USD ($)facility	Mar. 31, 2019USD ($)	Dec. 31, 2017USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)
Income Tax Disclosure [Abstract]
Income tax expense (benefit)		$ (104)	$ (1,028)
Contingent liability expense		$ 9,500
Tax Cuts and Jobs Act, additional income tax expense				$ 5,500
Number of nursing center facilities terminated | facility		10
Deferred tax asset, valuation allowance					$ 21,500	$ 20,000
CARES Act, tax refund received	$ 321

EARNINGS PER COMMON SHARE - Ba

EARNINGS PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net loss
Loss from continuing operations	$ (510)	$ (1,574)
Loss from discontinued operations, net of income taxes	(243)	(1,772)
Net loss	$ (753)	$ (3,346)
Per common share – basic
Loss from continuing operations (in dollars per share)	$ (0.08)	$ (0.24)
Loss from discontinued operations (dollars per share)	(0.04)	(0.28)
Net loss per common share – basic (dollars per share)	(0.12)	(0.52)
Per common share – diluted
Loss from continuing operations (dollars per share)	(0.08)	(0.24)
Loss from discontinued operations (dollars per share)	(0.04)	(0.28)
Net income (loss) per common share – diluted (dollars per share)	$ (0.12)	$ (0.52)
Weighted Average Common Shares Outstanding:
Basic (shares)	6,506	6,424
Diluted (shares)	6,506	6,424

EARNINGS PER COMMON SHARE - Na

EARNINGS PER COMMON SHARE - Narrative (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Antidilutive shares excluded from computation of diluted earnings per share (shares)	75	99

BUSINESS DEVELOPMENTS AND OTH_2

BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Narrative (Details)	Oct. 01, 2018extensioncenter	Mar. 31, 2020facilitycenter	Sep. 01, 2019center	Aug. 30, 2019facility	May 13, 2019center	Apr. 30, 2019center	Mar. 31, 2019center
Business Acquisition [Line Items]
Number of nursing center facilities leased	34	47
Number of skilled nursing centers under lease	23
Operating lease, initial term	12 years
Number of lease extensions allowed | extension	2
Lease extension period	10 years
Number of nursing center facilities terminated | facility		10
Annual lease fixed escalators, percent	2.15%
Number of skilled nursing centers participating in QIPP			12		4	11	1
Omega Healthcare Investors Inc
Business Acquisition [Line Items]
Number of nursing center facilities leased	11
Discontinued Operations | Kentucky Properties
Business Acquisition [Line Items]
Number of nursing center facilities terminated | facility				10

DISCONTINUED OPERATIONS - Narra

DISCONTINUED OPERATIONS - Narrative (Details) $ in Thousands	Aug. 30, 2019USD ($)facilitybed	Dec. 01, 2018USD ($)	Mar. 31, 2020USD ($)facility	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of nursing center facilities terminated | facility			10
Revenues contributed from centers				$ 16,803
Net income (loss) from centers			$ (243)	$ (1,772)
Kentucky Properties | Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of nursing center facilities terminated | facility	10
Number of skilled nursing beds terminated | bed	885
Pretax gain on transaction	$ 733
Kentucky Properties
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets		$ 18,700
Carrying value of centers						$ 13,331
Gain on disposition of assets					$ 4,825

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($)	Apr. 03, 2020	Dec. 01, 2018	Feb. 26, 2016	Apr. 30, 2020	Apr. 02, 2020	Mar. 31, 2020	May 13, 2019	Jun. 30, 2017	Oct. 03, 2016
Subsequent Event
Subsequent Event [Line Items]
CARES, Medicare stimulus funds received				$ 9,000,000
CARES, additional funds to be received				700,000
CARES, Medicare related to rate received				$ 900,000
Amended revolver | Amended and restated credit agreement
Subsequent Event [Line Items]
Repayments of lines of credit		$ 4,947,000
Borrowing capacity		42,250,000				$ 32,108,000	$ 5,000,000	$ 52,250,000	$ 52,250,000
Amended revolver | Amended and restated credit agreement | Acquisition loan facility
Subsequent Event [Line Items]
Repayments of lines of credit		2,100,000
Borrowing capacity		$ 10,400,000
Amended revolver | Amended and restated credit agreement | Acquisition loan facility | Subsequent Event
Subsequent Event [Line Items]
Borrowing capacity	$ 12,500,000
Threshold for eligible accounts receivable (in days)	150 days				120 days
LIBOR | Amended revolver | Amended and restated credit agreement
Subsequent Event [Line Items]
Interest rate percentage			4.00%
LIBOR | Amended revolver | Amended and restated credit agreement | Subsequent Event
Subsequent Event [Line Items]
Interest rate percentage	0.50%